Clinical evaluation of tigecycline in the treatment of nosocomial infections in a hospital in Taiwan

Man Tzu Marcie Wu, Hsiang Yin Chen, Tsong Yih Ou, Li Na Kuo, Kuei Ju Cheng, Wen Sen Lee

研究成果: 雜誌貢獻文章

3 引文 (Scopus)

摘要

Objective: Clinical information on tigecycline use in serious nosocomial infections is limited, and the efficacy is uncertain. The aim of this retrospective study was to assess the utilization pattern and the effectiveness of tigecycline in a tertiary medical center in Taiwan. Methods: A retrospective study of the clinical and microbiological outcome of all patients treated with tigecycline for at least 72 hours over a 2-year period was conducted in a 730-bed teaching hospital. Results: Data from 133 patients with 149 cases of nosocomial infection were analyzed in this assessment. The mean APACHE II score at the initiation of tigecycline therapy was 22.5 ± 8.8, and the mean duration of treatment was 11.4 ± 5.6 days. Pneumonia was the most frequently diagnosed clinical indication for tigecycline use (113 cases, 76%). An overall positive clinical outcome was observed in 75 cases (50%). Multidrug-resistant Acinetobacter baumannii (MDRAB) is the most common organism for tigecycline therapy (n = 59), with a positive clinical outcome of 38% in tigecycline monotherapy, 66% in dualtherapy, and 17% in triple-therapy (p = 0.031). The most commonly used combining agents with tigecycline to treat MDRAB infections were intravenous colistin, inhaled colistin, and cepoferazone/sulbactam, with positive clinical outcome rates of 53%, 100%, and 80%, respectively. Admission to intensive care unit was identified as a predictive factor for negative clinical outcome. Conclusion: Our pneumonia-dominated study population demonstrated a lower clinical improvement rate of tigecycline compared to previous published data. Tigecycline monotherapy is not recommended for MDRAB infection, but colistin or cephoperazone/sulbactam combined with tigecycline seemed to yield a good clinical outcome for MDRAB infection.
原文英語
頁(從 - 到)1030-1036
頁數7
期刊International Journal of Clinical Pharmacology and Therapeutics
52
發行號12
DOIs
出版狀態已發佈 - 十二月 1 2014

指紋

Cross Infection
Taiwan
Acinetobacter baumannii
Acinetobacter Infections
Colistin
Therapeutics
Sulbactam
Pneumonia
tigecycline
Retrospective Studies
APACHE
Teaching Hospitals
Intensive Care Units

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

引用此文

@article{3680c743100b4072b44b58d8517e6a32,
title = "Clinical evaluation of tigecycline in the treatment of nosocomial infections in a hospital in Taiwan",
abstract = "Objective: Clinical information on tigecycline use in serious nosocomial infections is limited, and the efficacy is uncertain. The aim of this retrospective study was to assess the utilization pattern and the effectiveness of tigecycline in a tertiary medical center in Taiwan. Methods: A retrospective study of the clinical and microbiological outcome of all patients treated with tigecycline for at least 72 hours over a 2-year period was conducted in a 730-bed teaching hospital. Results: Data from 133 patients with 149 cases of nosocomial infection were analyzed in this assessment. The mean APACHE II score at the initiation of tigecycline therapy was 22.5 ± 8.8, and the mean duration of treatment was 11.4 ± 5.6 days. Pneumonia was the most frequently diagnosed clinical indication for tigecycline use (113 cases, 76{\%}). An overall positive clinical outcome was observed in 75 cases (50{\%}). Multidrug-resistant Acinetobacter baumannii (MDRAB) is the most common organism for tigecycline therapy (n = 59), with a positive clinical outcome of 38{\%} in tigecycline monotherapy, 66{\%} in dualtherapy, and 17{\%} in triple-therapy (p = 0.031). The most commonly used combining agents with tigecycline to treat MDRAB infections were intravenous colistin, inhaled colistin, and cepoferazone/sulbactam, with positive clinical outcome rates of 53{\%}, 100{\%}, and 80{\%}, respectively. Admission to intensive care unit was identified as a predictive factor for negative clinical outcome. Conclusion: Our pneumonia-dominated study population demonstrated a lower clinical improvement rate of tigecycline compared to previous published data. Tigecycline monotherapy is not recommended for MDRAB infection, but colistin or cephoperazone/sulbactam combined with tigecycline seemed to yield a good clinical outcome for MDRAB infection.",
keywords = "Medication use evaluation, Nosocomial infections, Tigecycline",
author = "Wu, {Man Tzu Marcie} and Chen, {Hsiang Yin} and Ou, {Tsong Yih} and Kuo, {Li Na} and Cheng, {Kuei Ju} and Lee, {Wen Sen}",
year = "2014",
month = "12",
day = "1",
doi = "10.5414/CP202220",
language = "English",
volume = "52",
pages = "1030--1036",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0946-1965",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "12",

}

TY - JOUR

T1 - Clinical evaluation of tigecycline in the treatment of nosocomial infections in a hospital in Taiwan

AU - Wu, Man Tzu Marcie

AU - Chen, Hsiang Yin

AU - Ou, Tsong Yih

AU - Kuo, Li Na

AU - Cheng, Kuei Ju

AU - Lee, Wen Sen

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Objective: Clinical information on tigecycline use in serious nosocomial infections is limited, and the efficacy is uncertain. The aim of this retrospective study was to assess the utilization pattern and the effectiveness of tigecycline in a tertiary medical center in Taiwan. Methods: A retrospective study of the clinical and microbiological outcome of all patients treated with tigecycline for at least 72 hours over a 2-year period was conducted in a 730-bed teaching hospital. Results: Data from 133 patients with 149 cases of nosocomial infection were analyzed in this assessment. The mean APACHE II score at the initiation of tigecycline therapy was 22.5 ± 8.8, and the mean duration of treatment was 11.4 ± 5.6 days. Pneumonia was the most frequently diagnosed clinical indication for tigecycline use (113 cases, 76%). An overall positive clinical outcome was observed in 75 cases (50%). Multidrug-resistant Acinetobacter baumannii (MDRAB) is the most common organism for tigecycline therapy (n = 59), with a positive clinical outcome of 38% in tigecycline monotherapy, 66% in dualtherapy, and 17% in triple-therapy (p = 0.031). The most commonly used combining agents with tigecycline to treat MDRAB infections were intravenous colistin, inhaled colistin, and cepoferazone/sulbactam, with positive clinical outcome rates of 53%, 100%, and 80%, respectively. Admission to intensive care unit was identified as a predictive factor for negative clinical outcome. Conclusion: Our pneumonia-dominated study population demonstrated a lower clinical improvement rate of tigecycline compared to previous published data. Tigecycline monotherapy is not recommended for MDRAB infection, but colistin or cephoperazone/sulbactam combined with tigecycline seemed to yield a good clinical outcome for MDRAB infection.

AB - Objective: Clinical information on tigecycline use in serious nosocomial infections is limited, and the efficacy is uncertain. The aim of this retrospective study was to assess the utilization pattern and the effectiveness of tigecycline in a tertiary medical center in Taiwan. Methods: A retrospective study of the clinical and microbiological outcome of all patients treated with tigecycline for at least 72 hours over a 2-year period was conducted in a 730-bed teaching hospital. Results: Data from 133 patients with 149 cases of nosocomial infection were analyzed in this assessment. The mean APACHE II score at the initiation of tigecycline therapy was 22.5 ± 8.8, and the mean duration of treatment was 11.4 ± 5.6 days. Pneumonia was the most frequently diagnosed clinical indication for tigecycline use (113 cases, 76%). An overall positive clinical outcome was observed in 75 cases (50%). Multidrug-resistant Acinetobacter baumannii (MDRAB) is the most common organism for tigecycline therapy (n = 59), with a positive clinical outcome of 38% in tigecycline monotherapy, 66% in dualtherapy, and 17% in triple-therapy (p = 0.031). The most commonly used combining agents with tigecycline to treat MDRAB infections were intravenous colistin, inhaled colistin, and cepoferazone/sulbactam, with positive clinical outcome rates of 53%, 100%, and 80%, respectively. Admission to intensive care unit was identified as a predictive factor for negative clinical outcome. Conclusion: Our pneumonia-dominated study population demonstrated a lower clinical improvement rate of tigecycline compared to previous published data. Tigecycline monotherapy is not recommended for MDRAB infection, but colistin or cephoperazone/sulbactam combined with tigecycline seemed to yield a good clinical outcome for MDRAB infection.

KW - Medication use evaluation

KW - Nosocomial infections

KW - Tigecycline

UR - http://www.scopus.com/inward/record.url?scp=84937562905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937562905&partnerID=8YFLogxK

U2 - 10.5414/CP202220

DO - 10.5414/CP202220

M3 - Article

C2 - 25345432

AN - SCOPUS:84937562905

VL - 52

SP - 1030

EP - 1036

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0946-1965

IS - 12

ER -